Recent research at Washington University School of Medicine in St. Louis demonstrated that mature cells in the stomach sometimes revert back to behaving like rapidly dividing stem cells. Now, the researchers have found that this process may be universal; no matter the organ, when tissue responds to certain types of injury, mature cells seem to get younger and begin dividing rapidly, creating scenarios that can lead to cancer.
Older cells may be dangerous because when they revert to stem cell-like behavior, they carry with them all of the potential cancer-causing mutations that have accumulated during their lifespans. However, because mature cells in the stomach, pancreas, liver and kidney all activate the same genes and go through the same process when they begin to divide again, the findings could mean that cancer initiation is much more similar across organs than scientists have thought. That could support using the same strategies to treat or prevent cancer in a variety of different organs.
The findings about how mature cells begin dividing again -- a process the researchers have named paligenosis -- are reported Feb. 15 in The EMBO Journal.
"When we began the war on cancer in the 1970s, scientists thought all cancers were similar," said senior investigator Jason C. Mills, MD, PhD, a professor of medicine in the Division of Gastroenterology. "It turned out cancers are very different from one organ to another and from person to person. But if, as this study suggests, the way that cells become proliferative again is similar across many different organs, we can imagine therapies that interfere with cancer initiation in a more global way, regardless of where that cancer may appear in the body."
Studying cells from the stomach and pancreas in humans and mice, as well as mouse kidney and liver cells, and cells from more than 800 tumor and precancerous lesions in people, the researchers found when tissue is injured by infections or trauma, mature cells can revert back to a stem-cell state in which they divide repeatedly. And along the way, those cells all activate the same genes to break down the mature cells and help them begin to divide again.
"First, we saw a massive increase in the activity of genes associated with cell degradation," said first author Spencer G. Willet, PhD, a research associate in the Mills lab. "Then, the cell's growth pathway senses that degradation and releases nutrients that then activate cell growth pathways and allow the mature cells we studied to proliferate."
Paligenosis, Mills explained, appears similar to apoptosis -- the programmed death of cells as a normal part of an organism's growth and development -- in that it seems to happen the same way in every cell, regardless of its location in the body.
"Nature has provided a way for mature cells to begin dividing again," Mills said, "and that process is the same in every tissue we've studied."
Willet, Mills and their colleagues believe the discovery that cells in different organs go through the same process to become proliferative could lead to new potential targets for cancer treatment because the factors that initiate tumors could be the same in multiple organs.
"If you were to compare this reprogramming of cells to tearing down a building and putting something new in its place, the slow way to go would be to remove and then replace each brick, one at a time," Mills said. "What we're seeing is that nature is smarter than just running the building program in reverse. Instead, there is a wrecking ball program: When an old cell begins to divide again, a program runs to clear things out and then rebuild, and the same program runs in every tissue we've analyzed."
Willet SG, et al. Differentiated cells become regenerative in diverse biological contexts using a common program: paligenosis. The EMBO Journal, Feb. 21, 2018.
This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of General Medical Sciences, the National Cancer Institute and the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH), grant numbers R01 DK094989, R01 DK105129, R01 DK110406, P30 CA091842, CA00954731, 5T32GM007067-43, GM007067, HL38180, DK112378. DK56260 and P30 DK052574. Additional funding provided by the Alvin J. Siteman Cancer Center/Barnes Jewish Hospital Foundation Cancer Frontier Fund, the Barnard Trust, The DeNardo Education & Research Foundation, the Philip and Sima Needleman Student Fellowship in Regenerative Medicine, and the National Natural Science Foundation of China.
Washington University School of Medicine's 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked seventh in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.